Cerevel Therapeutics Hldg Stock (NASDAQ: CERE)

Cerevel Therapeutics Hldg (NASDAQ:CERE) Stock, Quote.Headers.trade-ideas

Cerevel Therapeutics Hldg

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Parkinsons disease

Biotech

News

Health Care

General

ABBV

CERE

Discover toplines results of Cerevel Therapeutics&#39; Phase 3 TEMPO-3 trial for tavapadon in Parkinson&#39;s disease treatment. Statistically significant efficacy and safety findings were revealed.

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson&#39;s Disease Study

abbvie shutter

Large Cap

Movers

LABP

AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis &amp; Crohn&#39;s disease.

Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?

laboratory-563423_1920

Analyst Color

Equities

Price Target

Initiation

Analyst Ratings

Trading Ideas

BHVN

KRTX

XENE

Biohaven&#39;s potential with RBC Capital Markets&#39; optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset Kv7-7000&#39;s Phase 3 trial this year, reducing late-stage risks.

This Analyst Is Bullish On Biohaven&#39;s Approach in Neuro-Psych Space

Cerevel Therapeutics Holdings, Inc. - Common Stock

Cerevel Therapeutics Holdings Inc

Cere Network

Cerence Inc

CERES GLOBAL AG CORP ORD by Ceres Global Ag Corp.

Ceres Global Ag Corp

Ceres Inc

CERES POWER HLDGS PLC by Ceres Power Holdings plc

Ceres Power Holdings PLC

CERES PWR HLDGS UNSP/ADR by Ceres Power Holdings plc

CERES VENTURES INC by Ceres Ventures, Inc.

Ceres Ventures Inc

High-rolling investors have positioned themselves bearish on Cerevel Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CERE often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 16 options trades for Cerevel Therapeutics Hldg. This is not a typical pattern.
The sentiment among these major traders is split, with 12% bullish and 87% bearish. Among all the options we identified, there was one put, amounting to $199,000, and 15 calls, totaling $853,002.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $42.5 for Cerevel Therapeutics Hldg during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Cerevel Therapeutics Hldg's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Cerevel Therapeutics Hldg's substantial trades, within a strike price spectrum from $35.0 to $42.5 over the preceding 30 days.
<h3>Cerevel Therapeutics Hldg 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721940425_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$0.3</td>
<td>$0.2</td>
<td>$0.4</td>
<td>$40.00</td>
<td>$199.0K</td>
<td>8.3K</td>
<td>5.1K</td>
</tr>
<tr>
<td>CERE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.35</td>
<td>$2.25</td>
<td>$2.25</td>
<td>$42.50</td>
<td>$87.3K</td>
<td>8.2K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CERE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.35</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$42.50</td>
<td>$85.1K</td>
<td>8.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>CERE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.45</td>
<td>$2.4</td>
<td>$2.45</td>
<td>$42.50</td>
<td>$83.7K</td>
<td>743</td>
<td>418</td>
</tr>
<tr>
<td>CERE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.0</td>
<td>$9.8</td>
<td>$9.8</td>
<td>$35.00</td>
<td>$66.6K</td>
<td>2.0K</td>
<td>196</td>
</tr>
</tbody>
</table>

<h3>About Cerevel Therapeutics Hldg</h3>
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
<h3>Where Is Cerevel Therapeutics Hldg Standing Right Now?</h3>
<ul>
<li>With a trading volume of 7,024,720, the price of CERE is up by 2.37%, reaching $44.4.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 11 days from now.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cerevel Therapeutics Hldg options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Check Out What Whales Are Doing With CERE

WIIM

Cerevel Therapeutics shares are trading lower amid unconfirmed rumors of a recommendation memo from FTC staff to challenge the AbbVie merger.

Rumors

Watching Cerevel Therapeutics; Traders Circulating M&A Blog Comments Saying A Recommendation Memo From The Staff At The FTC To "Challenge" The CERE/ABBV Merger Is Being Considered

Legal

Cerevel Therapeutics Shares Trading Higher Amid Circulation Of Rumors That The FTC Closed Door Meeting May Be About The Co's Merger With Tempur Sealy International

Deep-pocketed investors have adopted a bearish approach towards Cerevel Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CERE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Cerevel Therapeutics Hldg. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 11% leaning bullish and 44% bearish. Among these notable options, 3 are puts, totaling $1,610,000, and 6 are calls, amounting to $2,533,925.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $35.0 and $42.5 for Cerevel Therapeutics Hldg, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cerevel Therapeutics Hldg stands at 2521.71, with a total volume reaching 13,585.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cerevel Therapeutics Hldg, situated within the strike price corridor from $35.0 to $42.5, throughout the last 30 days.
<h3>Cerevel Therapeutics Hldg 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719342233_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$2.75</td>
<td>$0.35</td>
<td>$2.35</td>
<td>$40.00</td>
<td>$940.0K</td>
<td>1.7K</td>
<td>4.0K</td>
</tr>
<tr>
<td>CERE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.7</td>
<td>$3.0</td>
<td>$3.3</td>
<td>$40.00</td>
<td>$660.0K</td>
<td>92</td>
<td>2.1K</td>
</tr>
<tr>
<td>CERE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$3.2</td>
<td>$2.5</td>
<td>$2.6</td>
<td>$40.00</td>
<td>$650.0K</td>
<td>575</td>
<td>19</td>
</tr>
<tr>
<td>CERE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.5</td>
<td>$3.0</td>
<td>$3.25</td>
<td>$40.00</td>
<td>$650.0K</td>
<td>92</td>
<td>105</td>
</tr>
<tr>
<td>CERE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$1.65</td>
<td>$0.1</td>
<td>$1.3</td>
<td>$35.00</td>
<td>$520.0K</td>
<td>2.0K</td>
<td>4.0K</td>
</tr>
</tbody>
</table>

<h3>About Cerevel Therapeutics Hldg</h3>
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
<h3>Cerevel Therapeutics Hldg's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 5,459,634, the CERE's price is down by 0.0%, now at $41.42. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 37 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cerevel Therapeutics Hldg, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on CERE Options

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CERE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$40.00</td>
<td>$56.0K</td>
<td>3</td>
<td>2.9K</td>
</tr>
<tr>
<td>LFMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.50</td>
<td>$54.4K</td>
<td>2.3K</td>
<td>836</td>
</tr>
<tr>
<td>INCY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$60.00</td>
<td>$57.5K</td>
<td>6.3K</td>
<td>664</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$110.00</td>
<td>$43.0K</td>
<td>3.0K</td>
<td>362</td>
</tr>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$30.00</td>
<td>$378.0K</td>
<td>308</td>
<td>303</td>
</tr>
<tr>
<td>EXAS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$47.50</td>
<td>$29.4K</td>
<td>1.5K</td>
<td>181</td>
</tr>
<tr>
<td>BMRN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$75.00</td>
<td>$32.3K</td>
<td>525</td>
<td>68</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$115.00</td>
<td>$33.9K</td>
<td>20</td>
<td>32</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$30.00</td>
<td>$66.0K</td>
<td>1.2K</td>
<td>26</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$60.00</td>
<td>$31.9K</td>
<td>2.8K</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding CERE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>), we observe a put option trade with neutral sentiment. It expires in 45 day(s) on July 19, 2024. Parties traded 400 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $56.0K, with a price of $140.0 per contract. There were 3 open contracts at this strike prior to today, and today 2910 contract(s) were bought and sold. 
• For LFMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>), we notice a call option sweep that happens to be bullish, expiring in 164 day(s) on November 15, 2024. This event was a transfer of 389 contract(s) at a $7.50 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $54.4K, with a price of $140.0 per contract. There were 2327 open contracts at this strike prior to today, and today 836 contract(s) were bought and sold. 
• For INCY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), we notice a call option trade that happens to be bearish, expiring in 17 day(s) on June 21, 2024. This event was a transfer of 500 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $57.5K, with a price of $115.0 per contract. There were 6331 open contracts at this strike prior to today, and today 664 contract(s) were bought and sold. 
• For ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on August 16, 2024. This event was a transfer of 336 contract(s) at a $110.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $128.0 per contract. There were 3029 open contracts at this strike prior to today, and today 362 contract(s) were bought and sold. 
• For NVAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), we notice a put option trade that happens to be bullish, expiring in 45 day(s) on July 19, 2024. This event was a transfer of 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $378.0K, with a price of $1260.0 per contract. There were 308 open contracts at this strike prior to today, and today 303 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a put option sweep that happens to be bullish, expiring in 17 day(s) on June 21, 2024. This event was a transfer of 67 contract(s) at a $47.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $29.4K, with a price of $440.0 per contract. There were 1546 open contracts at this strike prior to today, and today 181 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a put option trade with bearish sentiment. It expires in 227 day(s) on January 17, 2025. Parties traded 66 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $32.3K, with a price of $490.0 per contract. There were 525 open contracts at this strike prior to today, and today 68 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option trade that happens to be bullish, expiring in 199 day(s) on December 20, 2024. This event was a transfer of 32 contract(s) at a $115.00 strike. The total cost received by the writing party (or parties) was $33.9K, with a price of $1060.0 per contract. There were 20 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option sweep with bullish sentiment. It expires in 227 day(s) on January 17, 2025. Parties traded 22 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $66.0K, with a price of $3000.0 per contract. There were 1261 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bullish sentiment. It expires in 17 day(s) on June 21, 2024. Parties traded 20 contract(s) at a $60.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1599.0 per contract. There were 2846 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMRN

DXCM

EXAS

INCY

LFMD

NVAX

VKTX

10 Health Care Stocks Whale Activity In Today's Session

On Thursday,&nbsp;Cerevel Therapeutics Holdings Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38309408/cerevel-therapeutics-announces-positive-topline-results-for-tavapadon-in-phase-3-adjunctive-trial-" rel="noreferrer noopener">Parkinson&#8217;s disease</a>.&nbsp;
The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults.&nbsp;
The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total &#8220;on&#8221; time without troublesome dyskinesia compared to those treated with LD and placebo (1.7 hours vs. 0.6 hours, p &lt;0.0001).&nbsp;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals" rel="noreferrer noopener">AbbVie&#8217;s New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals</a>.
A statistically significant reduction in &#8220;off&#8221; time, the key secondary endpoint, was also observed for the tavapadon treatment arm.
&#8220;Tavapadon&#8217;s novel mechanism of action, which selectively activates the D1/D5 dopamine receptors, has demonstrated the potential to provide people living with Parkinson&#8217;s disease the right balance of motor control, safety, and tolerability,&#8221; said Raymond Sanchez, M.D., chief medical officer, Cerevel Therapeutics.
Tavapadon was generally well tolerated. The safety profile observed in the TEMPO-3 trial was consistent with prior clinical trials of tavapadon.&nbsp;
The majority of adverse events reported were mild to moderate in severity.
Full results from the TEMPO-3 study will be submitted for presentation at future medical meetings and used to support regulatory submissions of tavapadon as a treatment for Parkinson&#8217;s disease.&nbsp;
Topline results from the Phase 3 monotherapy trials for tavapadon, TEMPO-1, and TEMPO-2 are expected in the second half of 2024.
In December,&nbsp;AbbVie Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) agreed to acquire&nbsp;Cerevel Therapeutics&nbsp;for a total equity value of approximately $8.7 billion, or $45 per share in cash. The transaction is anticipated to close<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36123803/why-cerevel-therapeutics-holdings-is-moving-after-hours" rel="noreferrer noopener">&nbsp;in mid-2024</a>.
Price Action: CERE shares are up 1.08% at $42.05 at the last check Thursday.
Photo by Milad Fakurian on Unsplash

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo

Monday,&nbsp;AbbVie Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) agreed to acquire&nbsp;Landos Biopharma Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LABP#NASDAQ">LABP</a>) for $20.42 per share, or approximately $137.5 million in the aggregate, plus one contingent value right per share with a value of up to $11.14 per share, or&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/n37911981/abbvie-to-acquire-landos-biopharma-further-strengthening-its-portfolio-in-inflammatory-and-autoimm" rel="noreferrer noopener">approximately an additional $75 million</a>.
The proposed transaction is expected to close in the second calendar quarter of 2024.
Landos&#8217; lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), anti-inflammatory, and facilitates epithelial repair.
&#8220;With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn&#8217;s disease,&#8221; said Roopal Thakkar, senior vice president, chief medical officer, global therapeutics, AbbVie.
NLRX1 regulates immuno-metabolism and inflammation, and its activation impacts multiple mechanisms of inflammatory bowel disease pathogenesis.&nbsp;
The randomized controlled Phase 2 NEXUS clinical trial evaluating NX-13 in ulcerative colitis is currently enrolling patients in the United States and Europe.
Also on Friday, the FDA granted full approval for Elahere (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/n37898296/u-s-food-and-drug-administration-fda-grants-full-approval-for-elahere-mirvetuximab-soravtansine-gy" rel="noreferrer noopener">with up to three prior therapies</a>.&nbsp;
Elahere was first granted FDA accelerated approval in November 2022, and the conversion to full approval is based on data from the confirmatory Phase 3 MIRASOL trial.&nbsp;
AbbVie added Elahere via the acquisition of&nbsp;ImmunoGen&nbsp;for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/36020779/immunogens-flagship-cancer-therapy-draws-abbvies-attention-with-10-1b-deal" rel="noreferrer noopener">approximately $10.1 billion</a>.&nbsp;
In December, AbbVie agreed to acquire&nbsp;Cerevel Therapeutics Holdings Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) for a total equity value of approximately $8.7 billion, or $45 per share in cash, expanding&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals" rel="noreferrer noopener">its foothold in neuroscience</a>.
Price Action: LABP shares are up 174.6% at $21.54 on the last check Monday.
Photo via Shutterstock

Mizuho analyst Graig Suvannavejh maintains Cerevel Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) with a Neutral and raises the price target from $25 to $45.

Mizuho Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $45

RBC Capital Markets&nbsp;has initiated&nbsp;Biohaven Ltd&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>), noting optimized&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/BHVN" rel="noreferrer noopener">development across programs</a>.
The analyst highlights the company&#8217;s way of identifying promising technologies and targets and leveraging its management expertise to optimize the development path based on competitor data to become a fast follower in high-value therapeutic areas.&nbsp;
RBC analyst says the Kv7 modulators are an exciting new mechanism in the neuro-psych space with a blockbuster potential of $3.2 billion across epilepsy and mood disorders and, like Biohaven&#8217;s approach of leveraging learnings from competitor&nbsp;Xenon Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) to accelerate its development path.&nbsp;
RBC has initiated Biohaven with an Outperform, Speculative Risk rating,&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/BHVN/analyst-ratings" rel="noreferrer noopener">and a price target of $62</a>.&nbsp;
The analyst sees potential for BHV-7000 to differentiate and close the gap to key competitor Xenon.
RBC recognizes the limited effectiveness data and potential risks associated with formulation changes. However, RBC expresses optimism about the distinctive safety profile of Biohaven&#8217;s BHV-7000 and perceives its mechanism as largely derisked.&nbsp;
Drawing parallels with the success of&nbsp;Karuna Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) and&nbsp;Cerevel Therapeutics Holdings Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) in the schizophrenia market, RBC believes that both BHV-7000 and Xenon&#8217;s XEN1101 can thrive in the epilepsy and mood disorder market, foreseeing increased adoption of this drug class facilitated by both companies.
RBC Capital anticipates that the lead asset Kv7-7000 holds exceptional potential in treating epilepsy and mood disorders.&nbsp;
The upcoming Phase 3 trial results expected this year could significantly reduce late-stage development risks, offering substantial opportunities upon successful outcomes.&nbsp;
Despite the inherent risks associated with clinical trials, a capable management team with a track record of success and various upcoming catalysts reinforces belief in the long-term value of Biohaven&#8217;s shares as its programs progress, RBC notes.
Price Action: BHVN shares are up 1.28% at $49.74 on the last check Friday.
Photo via Wikimedia Commons

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space

UBS&nbsp;initiated coverage on&nbsp;Axsome Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>), a biotech firm focused on developing and marketing therapies for central nervous disorders.&nbsp;
UBS analyst is bullish on Axsom&#8217;s depression drug Auvelity&#8217;s launch and pipeline opportunities with upcoming late-stage clinical read-outs.&nbsp;
Related Content:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36788978/axsome-depression-drugs-commercial-success-pipeline-potential-undervalued-analyst-says" rel="noreferrer noopener">Axsome Depression Drug&#8217;s Commercial Success, Pipeline Potential Undervalued, Analyst Says</a>.
The analyst anticipates that Auvelity could become a leading brand in depression treatment, generating $1 billion in sales by 2030; UBS&#8217;s bottom-up analysis shows that Auvelity can achieve near-term consensus estimates.&nbsp;
UBS initiates coverage with a Buy rating and a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/AXSM/analyst-ratings" rel="noreferrer noopener">price target of $111</a>.
Positive data in Phase 3 trials for Alzheimer&#8217;s Agitation and Narcolepsy is expected to boost the performance of Axsome Therapeutics&#8217; stock.&nbsp;
The stock is currently benefiting from increased investor interest in the central nervous system therapy sector, particularly after the strategic exit of some players, including:
<ul>
<li>Bristol Myers Squibb &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which agreed to acquire&nbsp;Karuna Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36360205/bristol-myers-squibb-scoops-up-schizophrenia-player-karuna-therapeutics-in-massive-14b-deal" rel="noreferrer noopener">estimated cash acquired</a>.&nbsp;</li>
<li>&nbsp;AbbVie Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) agreed to acquire&nbsp;Cerevel Therapeutics Holdings Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) for a total equity value of approximately $8.7 billion, or&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals" rel="noreferrer noopener">$45 per share in cash</a>.</li>
</ul>
Despite the current optimism, UBS analyst notes that the stock may be undervalued, with the market pricing in $2.0 billion in 2029 sales compared to the base case estimate of $2.4 billion.
In January, Axsome Therapeutics released preliminary fourth quarter 2023 product revenue of approximately $71 million and $204 million for&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/01/g36486683/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2023-net-revenue-and-2024-an" rel="noreferrer noopener">the full year of 2023</a>.
The company sees Auvelity&#8217;s net product sales to be approximately $49 million and $130 million for the fourth quarter and full year of 2023, respectively.
Sunosi&#8217;s revenue is expected to be $22 million and $74 million for the fourth quarter and full year of 2023, respectively.&nbsp;
The company will report fourth-quarter&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">financial results on February 20.</a>
Price Action:&nbsp;AXSM shares are up 2.39% at $93.69 on the last check Tuesday.

AXSM

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst

Friday,&nbsp;AbbVie Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.77</a>.
Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/n36907533/abbvie-reports-full-year-and-fourth-quarter-2023-financial-results" rel="noreferrer noopener">consensus of $14.02 billion</a>.
The immunology portfolio generated $6.95 billion in sales, down 12.3%.
Humira revenues were $3.30 billion (down 40.8%), Skyrizi sales reached $2.39 billion (up 51.9%), and Rinvoq revenues were $1.26 billion (up 62.9%).&nbsp;
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36592857/aesthetics-market-resilience-abbvie-asserts-widely-used-botox-dominance-amidst-rising-competition" rel="noreferrer noopener">Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition</a>.
Oncology product sales were $1.51 billion, down 7.4%. Imbruvica revenues were $903 million (down 19%), and Venclexta sales increased 14.3% to $589 million.
In November, AbbVie agreed to acquire&nbsp;ImmunoGen Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMGN#NASDAQ">IMGN</a>) and its flagship cancer therapy, Elahere, for $31.26 per share in cash, with an equity value of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/36020779/immunogens-flagship-cancer-therapy-draws-abbvies-attention-with-10-1b-deal" rel="noreferrer noopener">approximately $10.1 billion</a>.&nbsp;
Neuroscience revenues increased 22.6% to $2.09 billion. Botox Therapeutic sales were $776 million, up 6.6%.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36202496/botox-and-similar-injections-have-associated-risks-consumer-group-pushes-for-stronger-warnings" rel="noreferrer noopener">Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings</a>.
Aesthetics portfolio sales reached $1.37 billion, up 6.4%. Global Botox Cosmetic revenues were $718 million, up 11.8%.
During the quarter, AbbVie agreed to acquire&nbsp;Cerevel Therapeutics Holdings Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) for a total equity value of approximately $8.7 billion, or $45 per share in cash, to&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals" rel="noreferrer noopener">boost its neurological portfolio</a>.
Guidance: AbbVie expects fiscal year 2024 adjusted EPS of $11.05-$11.25, which includes a $0.32/share dilutive impact related to ImmunoGen and Cerevel Therapeutics acquisitions, versus the consensus of $11.29.
AbbVie is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029.&nbsp;
The company raised its long-term outlook for Skyrizi and Rinvoq revenues and expects combined 2027 revenues of over $27 billion, compared to over $21 billion expected earlier.
AbbVie also raised its long-term outlook for Ubrelvy and Qulipta and forecasts peak combined revenues of over $3 billion, up from previous guidance for peak revenues of over $1 billion for each asset.
Price Action: ABBV shares are up 1.44% at $170.01 on the last check Friday.
Photo via Shutterstock

Earnings

Guidance

IMGN

AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall

William Blair&nbsp;has upgraded&nbsp;AbbVie Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), noting confidence in the company&#8217;s growth outlook over the near and long term as it heads into 2024.
The analysts Tim Lugo, Lachlan Hanbury-Brown, and John Boyle write that 2023 was the year of transformation for AbbVie, marked by the introduction of Humira (arthritis) biosimilars and heightened competition for key franchises like Imbruvica (blood cancer drug) and Botox (cosmetic surgery).
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36592857/aesthetics-market-resilience-abbvie-asserts-widely-used-botox-dominance-amidst-rising-competition" rel="noreferrer noopener">Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition</a>.
Notably, AbbVie&#8217;s growth platform, led by Skyrizi and Rinvoq, has demonstrated strong performance, effective management of Humira erosion,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/36020779/immunogens-flagship-cancer-therapy-draws-abbvies-attention-with-10-1b-deal" rel="noreferrer noopener">and strategic acquisitions of</a>&nbsp;ImmunoGen Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMGN#NASDAQ">IMGN</a>) and&nbsp;Cerevel Therapeutics Holdings Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>).&nbsp;
These&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36123803/why-cerevel-therapeutics-holdings-is-moving-after-hours" rel="noreferrer noopener">acquisitions enhance the company&#8217;s</a>&nbsp;pipeline in crucial therapeutic areas such as solid tumor and neuroscience, positioning AbbVie for sustained growth throughout the remainder of the decade.
William Blair notes AbbVie&#8217;s highest dividend yield of 3.8% among domestic pharmaceutical companies experiencing significant top-line growth (&gt;1%) from 2024 to 2029.&nbsp;
Given AbbVie&#8217;s evident growth prospects in the short and long term, coupled with its reasonable valuation, the analysts find its shares attractive compared to those of its peers.
The analysts have upgraded the stock from&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/ABBV/analyst-ratings" rel="noreferrer noopener">Market Perform to Outperform</a>.
William Blair notes that although there is still some uncertainty about the future erosion of Humira and Imbruvica, the analysts show confidence that investors now have sufficient visibility to feel assured about AbbVie&#8217;s robust growth prospects in the near and long term.
AbbVie is set to release its fourth quarter 2023 earnings on 2 February. According to data from&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>, the company is expected to report an EPS of $2.81 with sales of $14.03 billion.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36202496/botox-and-similar-injections-have-associated-risks-consumer-group-pushes-for-stronger-warnings" rel="noreferrer noopener">Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings</a>.
Price Action:&nbsp;ABBV shares are down 0.12% at $164.21 on the last check Monday.

Upgrades

AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures

The 42nd annual JPMorgan Healthcare Conference kickstarts on Monday in San Francisco, California, and the four-day event will run through Thursday. The investment bank touts the conference as the &#8220;most informative health care investment symposium in the industry, which connects <a href="https://www.benzinga.com/general/biotech/22/01/24976697/bristol-myers-squibb-shares-jump-after-j-p-morgan-healthcare-conference-presentation">global industry leaders, </a>emerging fast-growth companies, innovative technology creators, and members of the investment community.&#8221;
What To Expect: The event will likely be attended by 8,000 people, including delegates from biopharma companies. Apart from conference presentations, JPMorgan will also host private, invite-only events for industry leaders on the sidelines of the conference. 
In the past, the event has served as a platform for discussing and announcing deals in the healthcare and biopharma spaces. With sentiment toward the sector improving in 2023 and M&amp;A transactions picking up pace after a lull period, it shouldn&#8217;t be surprising if more are announced at the conference. 
In December, Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) agreed to pay $14 billion for neuropsychiatry&nbsp;biotech Karuna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRTX#NASDAQ">KRTX</a>). Also during the month, AbbVie, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stitched up a $8.7 billion deal to buy neuroscience diseases-focused Cerevel Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>).
Companies could also choose to make preannouncements or update financial outlook, given the imminent onset of the fourth-quarter reporting season.
A lot of discussions could revolve around the use of artificial intelligence and robotics in healthcare, the new fad of weight-loss medications, and the healthcare and drug pricing reforms during the election year.
See Also: <a href="https://www.benzinga.com/money/best-biotech-stocks">Best Biotech Stocks</a>
Here&#8217;re some key presentations scheduled for Monday:
<ul>
<li>Bristol-Myers Squibb CEO Christopher Boerner will make a presentation and answer questions at 10:30 a.m. ET.</li>
<li>Vertex Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): CEO Dr.&nbsp;Reshma Kewalramani is scheduled to make a presentation at 11:15 a.m. ET. Ahead of its JPM appearance, the company issued a pipeline update on Sunday.</li>
<li>Amgen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): &nbsp;CEO Robert Bradway will present at 12 p.m. ET.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>): Senior management of the company will present at the conference at 12 p.m. ET.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>): The vaccine company&#8217;s CFO, Jamey Mock, will present at 6:45 p.m. ET.</li>
</ul>
Is Conference A Market Mover? The SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>), which tracks the performance of the S&amp;P Biotechnology Select Industry Index, has made an average gain of merely 0.76% over the past decade, STAT News said in a report. The report noted that there were outlier years as well, as in the case of 2016 &#8211; an election year when the index fell 7% during the conference week amid fears concerning drug pricing reforms. 
In 2019, when <a href="https://www.benzinga.com/general/biotech/19/01/12924561/bristol-myers-squibb-bets-big-on-celgene-in-74b-cash-and-stock-deal">Bristol-Myers lapped up Celgene, </a>the index was up about 8%, it added.
Even if the conference doesn&#8217;t move the broader sector, individual stocks could come under significant volatility depending on the news flow from presentations.
In premarket trading on Monday, the XBI edged down 0.27% to $89.06, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data.</a> The index gained 7.6% in 2023, rebounding from the previous year&#8217;s 26% slump.
Read Next: <a href="https://www.benzinga.com/general/biotech/24/01/36513924/strides-toward-lower-drug-costs-florida-becomes-first-to-receive-nod-to-import-prescription-drugs">Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada</a>

AMGN

MRNA

SRPT

VRTX

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.&nbsp;
Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&amp;A deals in&nbsp;<a class="editor-rtfLink" href="https://www.globaldata.com/store/report/healthcare-industry-m-and-a-deals-by-theme-quarterly-analysis/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Q3</a>&nbsp;2023.
PricewaterhouseCoopers&nbsp;<a class="editor-rtfLink" href="https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">wrote</a>&nbsp;in its Pharmaceutical and Life Sciences: U.S. Deals 2024 Outlook. &quot;As regulators&#39; perspectives on key deal factors become better understood, there may be a return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps.&quot;
&quot;Despite some stabilization in the macroeconomic environment and the potential for a soft landing in sight, continued geopolitical and regulatory uncertainty seems a given in 2024,&quot; PWC added in its report.
The pharmaceutical and life sciences sector experienced a notably robust year in 2023, nearing pre-pandemic levels in both M&amp;A deal value and volume, the PWC report added.&nbsp;
Anticipations for 2024 suggest continuing this trend, projecting comparable activity levels within the range of $225 billion to $275 billion across all subsectors.
Notable Deals in 2023
<ul>
<li>Pfizer Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) acquired&nbsp;Seagen Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgen#NASDAQ">SGEN</a>)<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/12/36198526/pfizer-clears-required-regulatory-hurdles-to-complete-43b-seagen-acquisition" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">&nbsp;for $43 billion.</a></li>
<li>Bristol Myers Squibb &amp; Co&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/bmy#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BMY</a>) agreed to acquire&nbsp;Karuna Therapeutics Inc&nbsp;KRTX for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/12/36360205/bristol-myers-squibb-scoops-up-schizophrenia-player-karuna-therapeutics-in-massive-14b-deal" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">estimated cash acquired</a>.&nbsp;</li>
<li>Merck &amp; Co&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) acquired&nbsp;Prometheus Biosciences&nbsp;for $200.00 per share in cash for a total equity&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/08/33491400/merck-swings-into-q2-loss-on-prometheus-biosciences-acquisition-charge-but-raises-fy23-revenue-ou" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">value of ~$10.8 billion</a>.</li>
<li>AbbVie Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abbv#NYSE">ABBV</a>) to acquire&nbsp;ImmunoGen Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imgn#NASDAQ">IMGN</a>) and its flagship cancer therapy Elahere, for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/11/36020779/immunogens-flagship-cancer-therapy-draws-abbvies-attention-with-10-1b-deal" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">approximately $10.1 billion</a>.&nbsp;</li>
<li>AbbVie Inc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abbv#NYSE">ABBV</a>) will acquire psychiatric and neurological disorders player&nbsp;Cerevel Therapeutics Holdings, Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/cere#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">CERE</a>) for $45 per share in cash with a total equity value of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/12/36138161/why-cerevel-therapeutics-stock-is-higher" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">approximately $8.7 billion</a>.</li>
<li>Biogen Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/biib#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BIIB</a>) agreed to acquire&nbsp;Reata Pharmaceuticals Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/reta#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">RETA</a>) for $172.50 per share in cash, reflecting an enterprise value of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/07/33440534/biogen-bolsters-rare-disease-portfolio-agrees-to-buy-reata-pharmaceuticals-with-enterprise-value-" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">approximately $7.3 billion</a>.</li>
<li>Bristol Myers Squibb &amp; Co&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/bmy#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BMY</a>) agreed to purchase&nbsp;Mirati&nbsp;Therapeutics Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/mrtx#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">MRTX</a>) at $58.00 per share in cash, amounting to an overall equity valuation of $4.8 billion, with an additional Contingent Value Right at $12.00 per share in cash, offering an extra&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/10/35141493/bristol-myers-squibb-strengthens-oncology-portfolio-with-mirati-therapeutics-5b-deal" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">$1.0 billion in value opportunity</a>.</li>
<li>Japanese healthcare company&nbsp;Astellas Pharma Inc&nbsp;(OTC:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/alpmy#OTC" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ALPMY</a>) has agreed to buy&nbsp;Iveric Bio Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/isee#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">ISEE</a>) for $40.00 per share in cash for a total equity value of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/23/05/32112605/astellas-pharma-acquires-iveric-bio-for-5-9b-to-focus-on-blindness-regeneration" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">approximately $5.9 billion</a>.</li>
<li>Most recently,&nbsp;Bristol Myers Squibb &amp; Co&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/bmy#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">BMY</a>) has agreed to acquire&nbsp;RayzeBio Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/ryzb#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">RYZB</a>) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/12/b36382478/bristol-myers-squibb-adds-premier-radiopharmaceutical-platform-with-acquisition-of-rayzebio" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">estimated cash acquired</a>.</li>
<li>Image by Steve Buissinne from Pixabay</li>
</ul>

ALPMY

BIIB

BMED

FHLC

Harvard Apparatus Regenerative Technology

HART

HTEC

ISEE

iShares Trust S&P Global Healthcare Sector Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

MDEV

MRTX

PINK

RETA

RYZB

SGEN

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024

JP Morgan has decided to maintain its Neutral rating of Cerevel Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) and raise its price target from $25.00 to $45.00.
Shares of Cerevel Therapeutics Hldg are trading up 0.47% over the last 24 hours, at $42.50 per share.
A move to $45.00 would account for a 5.88% increase from the current share price.
<h3>About Cerevel Therapeutics Hldg</h3>
Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know

JP Morgan analyst Jessica Fye maintains Cerevel Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) with a Neutral and raises the price target from $25 to $45.

JP Morgan Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $45

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>TD Cowen cut Paychex, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/payx#NASDAQ">PAYX</a>) price target from $132 to $123. TD Cowen analyst Bryan Bergin downgraded the stock from Outperform to Market Perform. Paychex shares fell 7% to close at $118.90 on Thursday. <a href="https://www.benzinga.com/quote/PAYX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays increased the price target for Carnival Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccl#NYSE">CCL</a>) from $22 to $24. Barclays analyst Brandt Montour maintained an Overweight rating. Carnival shares gained 6.2% to close at $19.19 on Thursday. <a href="https://www.benzinga.com/quote/CCL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies boosted the price target for Cerevel Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cere#NASDAQ">CERE</a>) from $40 to $45. Jefferies analyst Michael Yee downgraded the stock from Buy to Hold. Cerevel Therapeutics shares gained 0.2% to close at $41.39 on Thursday. <a href="https://www.benzinga.com/quote/CERE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut the price target for NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) from $132 to $128. Deutsche Bank analyst Gabriella Carbone maintained a Buy rating. NIKE shares rose 0.9% to close at $122.53 on Thursday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) from $17 to $32. HC Wainwright &amp; Co. analyst Joseph Pantginis maintained a Buy rating. Alpine Immune Sciences shares gained 4.1% to close at $19.73 on Thursday. <a href="https://www.benzinga.com/quote/ALPN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush boosted Tesla, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) price target from $310 to $350. Wedbush analyst Daniel Ives maintained an Outperform rating. Tesla shares gained 3% to close at $254.50 on Thursday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised Cintas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctas#NASDAQ">CTAS</a>) price target from $526 to $585. Stifel analyst Shlomo Rosenbaum maintained a Hold rating. Cintas shares gained 6.6% to close at $589.95 on Thursday. <a href="https://www.benzinga.com/quote/CTAS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted Teledyne Technologies Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdy#NYSE">TDY</a>) price target from $455 to $522. Needham analyst James Ricchiuti maintained a Buy rating. Teledyne Technologies shares gained 1% to close at $426.30 on Thursday. <a href="https://www.benzinga.com/quote/TDY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup increased Citizens Financial Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cfg#NYSE">CFG</a>) price target from $30 to $34. Citigroup analyst Keith Horowitz maintained a Neutral rating. Citizens Financial shares gained 1.6% to close at $32.91 on Thursday. <a href="https://www.benzinga.com/quote/CFG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut Duke Energy Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/duk#NYSE">DUK</a>) price target from $104 to $103. B of A Securities analyst Julien Dumoulin-Smith maintained a Buy rating. Duke Energy shares gained 0.7% to close at $96.36 on Thursday. <a href="https://www.benzinga.com/quote/DUK/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/23/12/36358246/nike-posts-downbeat-sales-joins-netease-and-other-big-stocks-moving-lower-in-fridays-pre-market-sess"> Nike Posts Downbeat Sales, Joins NetEase And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session </a>

Small Cap

ALPN

CTAS

PAYX

TSLA

Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday

Jefferies analyst Michael Yee downgrades Cerevel Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERE#NASDAQ">CERE</a>) from Buy to Hold and raises the price target from $40 to $45.

Downgrades

Jefferies Downgrades Cerevel Therapeutics Hldg to Hold, Raises Price Target to $45

Cerevel Therapeutics seesaws amid FTC notice on closed door meeting

Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal

Tempur Sealy seesaws amid FTC notice for closed door meeting

Cerevel Therapeutics gains on report Tempur Sealy will be the subject of FTC meeting

Cerevel Therapeutics gains on report Tempur Sealy will be the subject of FTC meeting (update)

AbbVie: A Hold Again (Rating Downgrade)

Cerevel Therapeutics drops amid report on FTC review of AbbVie deal

Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie

Cerevel ticks higher as AbbVie says it expects deal to close soon

Cerevel gains as AbbVie says it expects deal to close soon (update)

Press Releases

CEREVEL ALERT: Is $45 Per Share Too Low for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Urges Shareholders to Contact the Firm About Your Rights

CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm

CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investigating and Encourages Investors to Contact the Firm

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Cerevel Therapeutics Hldg

Cerevel Therapeutics Hldg (CERE) Forecast

Cerevel Therapeutics Hldg (NASDAQ:CERE) Stock, Quote.Headers.trade-ideas